IDTechEx will be hosting a free webinar on Thursday 11th January 2018 titled Invasive and non-invasive neural interfaces - Brain machine and brain computer interfaces

Raghu Das introduced the technologies covered and an introduction to the IDTechEx Show! USA 2017

As the point-of-care biosensor market is expected to expand to $33 billion by 2027, investing in the right technology and business model now is paramount to success over the next decade.

1.8 million people acquire HIV each year, with the World Health Organisation estimating that 1 in 5 people living with HIV do not realise they are infected. Therefore, strategies for faster and earlier diagnosis are as important as ever to limit the spread of HIV.

IDTechEx will be hosting a free webinar on Tuesday 21 November titled Medical Biosensors for Monitoring and Diagnostics.

Raghu Das, CEO and Chris Clare, Event Director, IDTechEx tells you what to expect at the upcoming IDTechEx Show! held at the Santa Clara Convention Center, November 15-16 2017.

What is a point-of-care device? Dr David Pugh et al. discuss how biosensors are changing the ways that diseases are diagnosed.

Connected healthcare is a transformative socio-technological model for healthcare management and delivery that leverages a range of technology innovations available today in order to provide optimized, flexible, targeted healthcare services.

Multifunctional probes are extremely useful for research purposes, as they allow the recording of neural activity simultaneously alongside stimulation via drug administration or light (as is the case with optogenetics).

European Commission's Horizon 2020 SME (small-medium sized enterprises) Instrument recently announced Sensars Neuroprosthetics as a Phase 1 recipient for funding of their SENSY technology. Phase 1 recipients receive €50000 in funding for 6 months to execute a feasibility study and draft a 10-page business proposal. This is intended to bring the technology from the idea to concept stage. There are currently 2813 participants, 2750 projects coordinated, and 1094,87M€ allocated to the Horizon 2020 SME Instrument.

IDTechEx's free, expert led webinars provide up-to-date insights on the latest emerging technology trends. You can now access these at a time that suits you, for up to one month.

The new IDTechEx Research report, Neuroprosthetics 2018-2028: Technologies, Forecasts, Players, covers the competitive landscape for cochlear implants, retinal implants and neuroprosthetic limbs, a market that is expected to reach $18 billion by 2028.

The University of Florida performs its first retinal implant with the Argus II by Second Sight. The Argus II is an epiretinal implant consisting of an inner electrode array placed in the eye where it can stimulate the remaining cells in the retina, effectively taking the place of the rod and cone cells that have died off due to degenerative retinal diseases like retinitis pigmetosa.

Doxorubicin, originally daunorubicin, is the result of a simultaneous discovery event in the 1950's between researchers in France and Italy. The molecule, a well-known anti-cancer drug used for a variety of indications ranging from acute lymphocytic leukemia to breast cancer, was approved for use in the United States in 1974.

Strong positive feedback and growth at Europe's most important event on emerging technologies

After over 15 years of research and development in academia and industry, several main applications of 3D bioprinting technology are ready to be realised.

On May 10-11 an estimated 3,000 people from over 40 countries will meet at the Estrel Convention Centre in Berlin to discuss the commercialization of a diverse range of emerging technologies.

The IDTechEx Show! in Berlin, Germany on 10-11 May is Europe's most important event for those involved in technology scouting and product innovation, bringing together emerging technologies with global brands.

Neural probes have long been a staple of neuroscience research, but in 1978 Dr. William Dobelle demonstrated they could do much more.

IDTechEx analyst Dr Laura Baers gives an overview of solar fuels and explains why artificial photosynthesis is still difficult to bring to market.